Literature DB >> 36118376

Short-Term Outcome in Patients Undergoing Gastrectomy with D2 Lymphadenectomy for Carcinoma Stomach.

Ganesh Vadthya1, Vishnu Prasad Nelamangala Ramakrishnaiah1, Srinivasan Krishnamachari1.   

Abstract

The safety and feasibility of D2 lymphadenectomy for gastric cancer in Western patients have been shown by Italian Gastric Cancer Study Group (IGCSG). In our center at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), we have been doing D1 lymphadenectomy all these years. Hence, this study was taken up to assess the feasibility of gastrectomy with D2 lymphadenectomy in patients with gastric cancer at JIPMER, Puducherry, India. Of the 148 carcinoma stomach patients explored, a total of 52 patients (35.13%) underwent resection with D1 (34 patients) or D2 (18 patients) lymphadenectomy, who formed the study groups. Patients were admitted and investigated by upper gastrointestinal endoscopy (UGIE) and other appropriate investigations including contrast-enhanced computed tomography (CECT) of the abdomen. Eligible patients had no serious comorbid cardiorespiratory disease that would preclude a safe D2 procedure. Two-third of the patients in both the groups belonged to the 50-75 age group. The mean number of nodes dissected was 6.44 ± 5.3 in the gastrectomy with D1 lymphadenectomy group versus 21.67 ± 5.3 in the gastrectomy with D2 lymphadenectomy group. There was no difference in the intraoperative blood loss, the number of units of blood transfused and the duration of surgery between D1 and D2 lymphadenectomy in our study. There was no difference between the postoperative stay and overall stay between the D1 and D2 lymphadenectomy. There was no significant difference between the overall morbidity and mortality or when the surgical complications were analysed individually. Intraoperative blood loss, the number of units of blood required for transfusion and the duration of surgery were not increased in D2 lymphadenectomy. The number of lymph nodes harvested was significantly more in D2 lymphadenectomy that resulted in a better staging. Postoperative morbidity or mortality in patients undergoing D2 lymphadenectomy was the same as in D1 lymphadenectomy. Hence, gastrectomy with D2 lymphadenectomy could be done safely. © Indian Association of Surgical Oncology 2017.

Entities:  

Keywords:  D1 lymphadenectomy; D2 lymphadenectomy; Gastric cancer; Morbidity; Mortality

Year:  2017        PMID: 36118376      PMCID: PMC9478051          DOI: 10.1007/s13193-017-0620-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  32 in total

1.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Okines; M Verheij; W Allum; D Cunningham; A Cervantes
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Prognostic significance and surgical management of lymph node metastasis in gastric cancer.

Authors:  M Noguchi; I Miyazaki
Journal:  Br J Surg       Date:  1996-02       Impact factor: 6.939

Review 3.  Present and future status of gastric cancer surgery.

Authors:  Makoto Saka; Shinji Morita; Takeo Fukagawa; Hitoshi Katai
Journal:  Jpn J Clin Oncol       Date:  2011-01-17       Impact factor: 3.019

4.  Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer.

Authors:  M Degiuli; M Sasako; A Ponti
Journal:  Br J Surg       Date:  2010-05       Impact factor: 6.939

5.  Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma.

Authors:  D M Dent; M V Madden; S K Price
Journal:  Br J Surg       Date:  1988-02       Impact factor: 6.939

6.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

7.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

Review 8.  Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer.

Authors:  P McCulloch; M Eidi Niita; H Kazi; J J Gama-Rodrigues
Journal:  Br J Surg       Date:  2005-01       Impact factor: 6.939

Review 9.  Surgery for gastric cancer: an evidence-based perspective.

Authors:  Melroy A D'souza; Kailash Singh; Shailesh V Shrikhande
Journal:  J Cancer Res Ther       Date:  2009 Oct-Dec       Impact factor: 1.805

Review 10.  An evidence-based medicine review of lymphadenectomy extent for gastric cancer.

Authors:  Sun Hu Yang; You Cheng Zhang; Ke Hu Yang; You Ping Li; Xiao Dong He; Jin Hui Tian; Ting Hong Lv; Ying Hua Hui; Neel Sharma
Journal:  Am J Surg       Date:  2008-08-22       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.